Histiocytic disorders in children consist of a broad group of disorders due to its common origin. It originates from the activated cells of the monocyte-macrophage system which commonly looks like the histiocytes. Langerhans cell histiocytosis (LCH) is one such disorder which is also known as histiocytosis X. Etoposide is sought to be an effective treatment for LCH.
But following its secondary malignancy and no label expansions as compared to vinblastine (Vbl), the use of etoposide was curtailed in LCH trials. Currently, Patients can afford first-line of therapy for LCH but they can’t afford the toxic chemotherapy and hematopoietic stem cell therapy. Therefore, management strategies like curtailing disease progression and reducing recurrences thereby could improve chances of survival. In this study, the impact of standard induction, augmentation with metronomic etoposide and prolonged…
